Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models

In-silico models were generated to predict the extent of inhibition of cytochrome P450 isoenzymes using a set of relatively interpretable descriptors in conjunction with partial least squares (PLS) and regression trees (RT). The former was chosen due to the conservative nature of the resultant models built and the latter to more effectively account for any non-linearity between dependent and independent variables. All models are statistically significant and agree with the known SAR and they could be used as a guide to P450 liability through a classification based on the continuous pIC50 prediction given by the model. A compound is classified as having either a high or low P450 liability if the predicted pIC50 is at least one root mean square error (RMSE) from the high/low pIC50 cut-off of 5. If predicted within an RMSE of the cut-off we cannot be confident a compound will be experimentally low or high so an indeterminate classification is given. Hybrid models using bulk descriptors and fragmental descriptors do significantly better in modeling CYP450 inhibition, than bulk property QSAR descriptors alone.

[1]  J. Edward Jackson,et al.  A User's Guide to Principal Components: Jackson/User's Guide to Principal Components , 2004 .

[2]  F C Lightstone,et al.  Quantitative structure‐activity relationship of flavonoids for inhibition of heterocyclic amine mutagenicity , 2000, Environmental and molecular mutagenesis.

[3]  Pierre Bruneau,et al.  Search for Predictive Generic Model of Aqueous Solubility Using Bayesian Neural Nets , 2001, J. Chem. Inf. Comput. Sci..

[4]  H. Wold.  Path Models with Latent Variables: The NIPALS Approach , 1975 .

[5]  Eric F. Johnson,et al.  The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution* , 2004, Journal of Biological Chemistry.

[6]  S. O'Brien,et al.  Greater than the sum of its parts: combining models for useful ADMET prediction. , 2005, Journal of medicinal chemistry.

[7]  A. Alex,et al.  A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.

[8]  Maurice Dickins,et al.  Compound lipophilicity for substrate binding to human P450s in drug metabolism. , 2004, Drug discovery today.

[9]  Andrew G. Leach,et al.  Matched molecular pairs as a guide in the optimization of pharmaceutical properties; a study of aqueous solubility, plasma protein binding and oral exposure. , 2006, Journal of medicinal chemistry.

[10]  Dennis A. Smith,et al.  Properties of cytochrome P450 isoenzymes and their substrates Part 2: properties of cytochrome P450 substrates , 1997 .

[11]  Leo Breiman,et al.  Classification and Regression Trees , 1984 .

[12]  C. Masimirembwa,et al.  In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery. , 2001, Combinatorial chemistry & high throughput screening.

[13]  Steven L. Dixon,et al.  Use of Robust Classification Techniques for the Prediction of Human Cytochrome P450 2D6 Inhibition , 2003, J. Chem. Inf. Comput. Sci..

[14]  Jose Cosme,et al.  Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.

[15]  Han van de Waterbeemd,et al.  Time‐Series QSAR Analysis of Human Plasma Protein Binding Data , 2007 .

[16]  F Peter Guengerich,et al.  Update Information on Human P450s , 2002, Drug metabolism reviews.

[17]  Jeffrey P. Jones,et al.  Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[18]  Jose Cosme,et al.  Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone , 2004, Science.

[19]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[20]  J. E. Jackson.  A User's Guide to Principal Components , 1991 .

[21]  Slobodan Petar Rendic,et al.  Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.

[22]  M Paul Gleeson,et al.  In silico human and rat Vss quantitative structure-activity relationship models. , 2006, Journal of medicinal chemistry.

[23]  R J Riley,et al.  Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[24]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[25]  Anders Karlén,et al.  Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors. , 2004, Journal of medicinal chemistry.

[26]  Robert J Riley,et al.  A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology. , 2003, British journal of clinical pharmacology.

[27]  Glenn J. Myatt,et al.  LeadScope: Software for Exploring Large Sets of Screening Data , 2000, J. Chem. Inf. Comput. Sci..

[28]  N S Lewis,et al.  The use of 'electronic nose' sensor responses to predict the inhibition activity of alcohols on the cytochrome P-450 catalyzed p-hydroxylation of aniline. , 2000, Bioorganic & medicinal chemistry.

[29]  R. J. Riley,et al.  Development of a Generalized, Quantitative Physicochemical Model of CYP3A4 Inhibition for Use in Early Drug Discovery , 2001, Pharmaceutical Research.

[30]  Frank E. Blaney,et al.  Crystal Structure of Human Cytochrome P450 2D6* , 2005, Journal of Biological Chemistry.

[31]  A. Y. Lu,et al.  Inhibition and Induction of Cytochrome P450 and the Clinical Implications , 1998, Clinical pharmacokinetics.

[32]  G. Schneider,et al.  A Virtual Screening Filter for Identification of Cytochrome P450 2C9 (CYP2C9) Inhibitors , 2007 .

[33]  M. Dickins,et al.  Quantitative Structure-Activity Relationships (QSARs) Within Substrates of Human Cytochromes P450 Involved in Drug Metabolism , 2001, Drug metabolism and drug interactions.

[34]  Bruce R. Kowalski,et al.  Chemometrics, mathematics and statistics in chemistry , 1984 .

[35]  Robert J Riley,et al.  The influence of DMPK as an integrated partner in modern drug discovery. , 2002, Current drug metabolism.

[36]  Scott Boyer,et al.  Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data , 2007, J. Comput. Aided Mol. Des..

[37]  C. Hansch,et al.  p-σ-π Analysis. A Method for the Correlation of Biological Activity and Chemical Structure , 1964 .

[38]  J. Ruuskanen,et al.  Performance of (consensus) kNN QSAR for predicting estrogenic activity in a large diverse set of organic compounds , 2004, SAR and QSAR in environmental research.

[39]  I. Pajeva,et al.  Quantitative structure-activity relationship (QSAR) and three-dimensional QSAR analysis of a series of xanthates as inhibitors and inactivators of cytochrome P450 2B1 , 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[40]  J. Platts,et al.  Correlation and prediction of a large blood-brain distribution data set--an LFER study. , 2001, European journal of medicinal chemistry.

[41]  David F. V. Lewis,et al.  Structure–activity relationship for human cytochrome P450 substrates and inhibitors , 2002, Drug metabolism reviews.

[42]  S. Ekins,et al.  Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[43]  Jeffrey P. Jones,et al.  A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions. , 2000, Journal of medicinal chemistry.

[44]  Luc Morin-Allory,et al.  2D QSAR Consensus Prediction for High-Throughput Virtual Screening. An Application to COX-2 Inhibition Modeling and Screening of the NCI Database , 2004, J. Chem. Inf. Model..

[45]  S. Wold,et al.  Multi‐way principal components‐and PLS‐analysis , 1987 .

[46]  M. Abraham,et al.  The correlation and prediction of the solubility of compounds in water using an amended solvation energy relationship. , 1999, Journal of pharmaceutical sciences.

[47]  M Paul Gleeson,et al.  Plasma protein binding affinity and its relationship to molecular structure: an in-silico analysis. , 2007, Journal of medicinal chemistry.

[48]  A. Tropsha,et al.  Beware of q2! , 2002, Journal of molecular graphics & modelling.

[49]  Jaina Mistry,et al.  A rapid computational filter for cytochrome P450 1A2 inhibition potential of compound libraries. , 2005, Journal of medicinal chemistry.

[50]  D. Lewis,et al.  Quantitative structure-activity relationships (QSARs) for substrates of human cytochromes P450 CYP2 family enzymes. , 2004, Toxicology in vitro : an international journal published in association with BIBRA.